دورية أكاديمية
Modulating expression of inhibitory and stimulatory immune 'checkpoints' using nanoparticulate-assisted nucleic acid delivery.
| العنوان: | Modulating expression of inhibitory and stimulatory immune 'checkpoints' using nanoparticulate-assisted nucleic acid delivery. |
|---|---|
| المؤلفون: | Walters AA; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom., Dhadwar B; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom., Al-Jamal KT; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom. Electronic address: Khuloud.al-jamal@kcl.ac.uk. |
| المصدر: | EBioMedicine [EBioMedicine] 2021 Nov; Vol. 73, pp. 103624. Date of Electronic Publication: 2021 Oct 20. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Amsterdam] : Elsevier B.V., [2014]- |
| مواضيع طبية MeSH: | Drug Delivery Systems* , Gene Expression Regulation* , Nanoparticles* , Theranostic Nanomedicine*, Immune Checkpoint Proteins/*genetics , Nucleic Acids/*administration & dosage, Animals ; Clinical Studies as Topic ; Drug Evaluation, Preclinical ; Humans ; Immune Checkpoint Proteins/metabolism ; Neoplasms/drug therapy ; Neoplasms/etiology ; Neoplasms/pathology ; Nucleic Acids/genetics ; Plasmids/administration & dosage ; Plasmids/chemistry ; RNA Interference ; RNA, Messenger/administration & dosage ; RNA, Messenger/genetics ; RNA, Small Interfering/administration & dosage ; RNA, Small Interfering/genetics ; Treatment Outcome |
| مستخلص: | Immune checkpoints are regulatory molecules responsible for determining the magnitude and nature of the immune response. The aim of immune checkpoint targeting immunotherapy is to manipulate these interactions, engaging the immune system in treatment of cancer. Clinically, the use of monoclonal antibodies to block immunosuppressive interactions has proven itself to be a highly effective immunotherapeutic intervention. Within the literature there are numerous candidates for next generation of immune checkpoint targeting strategies. One such example is the use of nucleic acid to alter expression levels of immune checkpoint molecules, either as antisense oligo nucleotides/siRNA, to downregulate inhibitory molecules, or mRNA/DNA, to express co-stimulatory molecules. A significant component of nucleic acid delivery is its formulation within a nanoparticulate system. In this review we discuss the progress of the preclinical application of nucleic acid-based immunotherapies to target a selection of co-inhibitory/co-stimulatory molecules. Furthermore, we identify the potential and current gaps within the literature which may form the basis of future work. Competing Interests: Declaration of competing Interest The authors declare that there is no conflict of interest. (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Immune checkpoint; Nanoparticle; RNA interference; siRNA |
| المشرفين على المادة: | 0 (Immune Checkpoint Proteins) 0 (Nucleic Acids) 0 (RNA, Messenger) 0 (RNA, Small Interfering) |
| تواريخ الأحداث: | Date Created: 20211023 Date Completed: 20220301 Latest Revision: 20220301 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8536530 |
| DOI: | 10.1016/j.ebiom.2021.103624 |
| PMID: | 34688033 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2352-3964 |
|---|---|
| DOI: | 10.1016/j.ebiom.2021.103624 |